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A B S T R A C T   
Imaging is increasingly more utilized as analytical technology in biopharmaceutical formulation research, with 
applications ranging from subvisible particle characterization to thermal stability screening and residual mois-
ture analysis. This review offers a comprehensive overview of analytical imaging for scientists active in bio-
pharmaceutical formulation research and development, where it presents the unique information provided by 
the ultraviolet (UV), visible (Vis), and infrared (IR) sections in the electromagnetic spectrum. The main body of 
this review consists of an outline of UV, Vis, and IR imaging techniques for several (bio)physical properties that 
are commonly determined during protein-based biopharmaceutical formulation characterization and develop-
ment studies. The review concludes with a future perspective of applied imaging within the field of biophar-
maceutical formulation research.   
1. Introduction 
Biopharmaceutical formulation characterization is an integral part of 
biopharmaceutical research and development, where insight is gener-
ated on the product’s critical quality attributes as a function of formu-
lation (processing) parameters, such as pH [1], excipients [2,3] or 
temperature [4]. This results from the Quality by Design (QbD) 
approach, which strives for a systematic development of biopharma-
ceutical products and their production processes based on predefined 
product quality characteristics [5]. Characterization studies are there-
fore essential to determine manufacturability as well as the safety and 
efficacy of biopharmaceutical products [6]. Some analytical techniques 
employed for characterization studies can also be applied as process 
analytical technology (PAT) to enable product quality monitoring dur-
ing processing for (near)-real time release applications, thereby mini-
mizing production and product quality risks [7]. Characterization 
studies utilize a wide range of analytical technologies to capture both 
biophysical protein properties, such as aggregation tendency [8] or 
thermal stability [9–11], and physical formulation properties, such as 
surface tension [12,13]. One of the analytical techniques applied for 
characterization studies is imaging, where an image is defined as a visual 
2-D spatial representation of the subject. Imaging is able to capture a 
multitude of characteristics as the format of an image has been expanded 
beyond a digital visible light image by using the breadth of the elec-
tromagnetic spectrum. In addition to its broad information content, the 
non-invasive nature of imaging is beneficial during biopharmaceutical 
characterization and development studies, as well as for PAT purposes, 
as product interference can lead to unrepresentative results. These at-
tributes make imaging a widely applicable analytical technique, but its 
full potential not yet reached for biopharmaceutical research and 
development studies as further optimization is needed, such as shorter 
acquisition times, (cost-competitive) multiplexed imaging equipment, 
and advanced data analytics. This review provides information to show 
the current role of analytical imaging and understand the role it will play 
in biopharmaceutical characterization and development studies upon 
realization of its full potential. This is done by presenting imaging 
techniques, the respective part of electromagnetic spectrum, an over-
view of current imaging possibilities, and the novel insight these ap-
plications have already generated. 
A general imaging setup is schematically shown in Fig. 1 and consists 
of emission by a light source (a), detection by means of an image 
acquisition device (b), and a processor and control unit (c). An image 
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acquisition device is employed to capture different types of light-matter 
interaction effects (d), namely transmitance, absorption, reflectance, 
scattering, or fluorescence. A depiction of each of these effects is shown 
in Fig. 1 as well. 
Transmittance refers to the degree of light passing through matter 
without any interaction. The term reflectance describes light beams that 
follow the law of reflection, where the incident photons are reflected 
under an equal angle, as well as diffuse reflection, where scattering of 
light occurs without photon energy absorption [14]. Absorbance de-
scribes the situation where a photon’s energy is absorbed by the 
respective matter. This occurs when a photon carries an energy that is 
similar to a certain molecular transition. As a photon’s energy is 
inversely proportional to its wavelength, different molecular transitions 
occur as a result of photon absorbance across the electromagnetic 
spectrum. An example of electron excitation [15] and vibrational tran-
sitions [16] is depicted in the Jablonski diagram in Fig. 1. Fluorescence 
occurs when an electron returns to its ground state from an excited 
electronic state induced by photon absorption. This return results in the 
emission of a photon with an energy equal to the energy difference 
between the excited and ground state [15,17]. The emitted photon 
carries a lower energy compared to the incident photon as some of the 
initially absorbed energy dissipates via non-radiative transitions, such as 
molecular relaxation [17]. 
The term scattering is used to define an event where incident photons 
interact with the respective matter and are subsequently emitted in 
different directions. This interaction results in an excitation to the so- 
called virtual state because the photon’s energy is not resonant with a 
molecular transition and is rapidly (<10− 15 s) followed by the emission 
of a photon upon returning to the ground state [18,19]. The emitted 
photons’ energy can remain similar (elastic scattering) or change (in-
elastic scattering) [19,20]. This is illustrated in the Jablonski diagram in 
Fig. 1, where elastic scattering shown by I and inelastic scattering is 
shown by II and III. The direction of elastic scattering is dependent on 
the size of the particle with respect to the wavelength of the incident 
photon. Rayleigh scattering occurs for particles with a size smaller than 
one-tenth of the wavelength, where the scattering is distributed in all 
directions. Forward scattering becomes dominant for particles larger 
than one-tenth of the photon’s wavelength, where Mie scattering occurs 
for particles between one-tenth and 1 time the wavelength. Optical 
scattering occurs for particles larger than the wavelength of the incident 
photon. Inelastic scattering results in the emission of a photon carrying a 
lower or higher energy than the incident photon, which is referred to as 
Raman Stokes (II, Fig. 1) or anti-Stokes (III, Fig. 1) scattering, respec-
tively [20]. Inelastic Raman scattering accounts only for approximately 
1 in 1010 incident photons [19,21]. As most molecules are in their 
ground state at ambient temperature, mostly Raman Stokes scattering 
occurs [22]. More information on Raman scattering is provided in Sec-
tion 2.4, where Raman scattering is discussed alongside infrared photon 
absorption. 
The employed wavelength of the light source can vary within the 
Fig. 1. A schematic of a general imaging setup, 
showing (a) emission by a light source, (b) detection 
by an image acquisition device, and (c) a processor 
and control unit, where orange lines indicate control 
and data transfer connections. The inset (d) refers to 
the five light-matter interaction effects employed for 
image acquisition, showing transmittance (brown), 
absorbance (red), reflectance (yellow), scattering 
(blue), and fluorescence (green) of an incoming light 
beam. A Jablonski diagram is shown below to illus-
trate the transitions for absorbance, scattering (I: 
Rayleigh scattering, II: Raman Stokes scattering, and 
III: Raman anti-Stokes scattering), and fluorescence. 
(For interpretation of the references to color in this 
figure legend, the reader is referred to the web 
version of this article.)   
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electromagnetic spectrum, of which a part is shown on the left side of 
Fig. 2. This review focuses on different regions of the electromagnetic 
spectrum ranging from ultraviolet (UV, 190 nm – 380 nm) to the far 
infrared (FIR, 30–1 mm) range, as these wavelengths cover the majority 
of imaging techniques relevant for protein-based biopharmaceutical 
characterization and development studies. 
The first part of the review presents the relevant and unique infor-
mation content of each region and is followed by a brief overview of 
required data analytical steps to extract and utilize the information 
content. The review continues with the application of the electromag-
netic spectrum wavelength regions, sectioned per (bio)physical property 
of protein-based biopharmaceutical products and/or the formulation. 
The review concludes with a future perspective on imaging trends and 
optimizations in the field of biopharmaceutical characterization and 
development research. 
2. Electromagnetic spectrum: Ultraviolet to far infrared (190–1 
mm) 
The UV to FIR (190–1 mm) range is a rich source of information, 
meaning the selection of a particular light source for an imaging tech-
nique depends on the desired (bio)physical property to extract or to 
represent. A general overview of the information content within the UV 
to FIR range is displayed on the right side in Fig. 2. The following sub-
sections concisely present the depicted information content, ordered per 
region within the UV to FIR range. 
2.1. Ultraviolet (190–380 nm) 
The UV region can be employed for reflective and fluorescent im-
aging purposes [23]. Of these two, only fluorescent UV imaging will be 
introduced in this review, as this technique is applied for protein-based 
biopharmaceutical characterization studies to determine the presence or 
spatial location of proteins. Proteins can be located as a result of intrinsic 
fluorescence of the aromatic amino acid tryptophan, tyrosine, and 
phenylalanine. These specific amino acids absorb photons with a 
wavelength in the UV region, with a maximum absorbance around 280, 
275, and 260 nm, respectively, and emit the residual energy at a 
maximum near 350, 300, and 280 nm, respectively [24]. Tryptophan 
plays a dominant role in UV imaging due to its emission wavelength and 
relatively high fluorescence quantum yield [25], where the fluorescence 
quantum yield determines the emission intensity. Fluorescence emission 
intensity can be strongly influenced by environmental factors, such as 
solution polarity or ionic strength [26] and resonance energy transfer to 
neighboring residues [27]. In addition to intrinsic protein fluorescence, 
extrinsic protein fluorescence is also applied for fluorescent imaging. 
Extrinsic fluorescence is achieved by adding fluorescent dyes that (non) 
covalently bind to protein molecules [28]. This procedure facilitates 
fluorescent imaging independent of the presence of aromatic amino 
acids and for a wider range of wavelengths (also outside the UV range) to 
enhance detection specificity. 
2.2. Visible light (380-750 nm) 
Visible light imaging is commonly used for the identification of ob-
jects and texture by means of reflectance, transmittance, and absor-
bance. Reflectance and transmittance imaging allow for the 
identification of objects, where reflectance provides information on the 
surface of the sample and transmittance provides surface and subsurface 
information [29]. Visible light imaging is also employed for the docu-
mentation of colors. Colors are commonly utilized to identify texture by 
evaluating the spatial distribution of color or shade levels, where texture 
is defined as a local variation that is too small to qualify as an object 
[30]. Object identification by means of transmittance is based on light 
obstruction, but this mode can also encounter uncontrollable obscura-
tion of the light path, which may block transmittance entirely. Thus, for 
transmittance imaging sample transparency needs to be considered. 
Contrast enhancement expands the information content of visible 
light images towards the type of matter that is captured as an object or 
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Fig. 2. Overview of the electromagnetic spectrum range discussed in this review (left) and a general indication of the corresponding information content (right).  
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illumination, phase contrast imaging, or differential interference 
contrast imaging, where additional hardware components are added or 
the hardware configuration is adjusted [31]. For example, light polari-
zation involves the implementation of a filter to obtain a light wave 
oscillation in a particular direction, which can be a single direction, a 
rotational direction, or under an angle, such as used for cross- 
polarization [32]. Polarized light can be used to distinguish between 
isotropic and anisotropic materials, such as crystals, because anisotropic 
material influences the direction of polarized light (birefringence) [33] 
and isotropic material does not. Dark-field illumination is an example of 
altering the angle between the light source and the image acquisition 
device to solely capture light that is reflected if objects interfere [34]. 
Such a change in configuration can be applied to obtain an improved 
detection of colorless or transparent objects. 
2.3. Thermal radiation (8–14 μm) 
Thermal radiation spans multiple electromagnetic spectrum regions 
and is defined as radiant energy that is solely due to the object’s tem-
perature [35]. The detection of temperature is of interest for protein- 
based biopharmaceutical characterization and development studies, as 
temperature is an environmental factor that influences proteins’ 
colloidal, conformational, and chemical stability [36]. Monitoring 
temperature via imaging is called thermography and it captures the rate 
with which thermal radiation leaves an object, where lower tempera-
tures result in longer wavelengths emitted with a lower intensity, and 
vice versa. This makes thermography notably different from other im-
aging techniques as thermography does not require a light source. Thus, 
a schematic image acquisition setup, such as depicted in Fig. 1, would be 
without an external emission source. Capturing the temperature of an 
object is sensitive to a multitude of object and environmental factors. 
Among the most relevant factors are the object’s surface area and 
emissivity (the degree of radiation of the material) as well as properties 
of the atmosphere, the temperature of surrounding material, and the 
angle and distance between the camera and the captured surface [37]. 
These dependencies result in the need for both object and surrounding 
characterization, as well as device calibration to obtain reliable output 
for analysis [37,38]. Three subsections in the infrared region are often 
used for thermography, namely 0.9 – 1.7 µm, 3 – 5 µm, and 8 – 14 µm, 
which are called the short-wave (SW), mid-wave (MW), and long-wave 
(LW) region, respectively. The LW region is considered most applicable 
for biopharmaceutical characterization purposes, as objects with rele-
vant temperatures (approximately from − 80 ◦C to 100 ◦C) emit most of 
the thermal radiation in this range and LW detection hardware is rela-
tively inexpensive while providing sufficient thermal sensitivity (order 
of magnitude of 0.05 ◦C) [38]. Nevertheless, MW-based thermography 
can also be applied for biopharmaceutical characterization purposes, 
where it may overcome issues with resolution, temperature contrast, 
and reflection that may be encountered with LW-based thermography 
[38]. 
2.4. Near- and mid-infrared (750–10 μm) 
As depicted in Fig. 2, the near- and mid-infrared region (NIR at 750 
nm to 2.5 μm and MIR at 2.5 μm to 30 μm, respectively) can be used to 
extract information on intramolecular vibrations via absorption or 
scattering profiles. Imaging in the MIR and NIR region obtains similar 
fundamental information as IR spectroscopic techniques, but in contrast 
to spectroscopy, imaging gathers multiple spectra in the spatial dimen-
sion instead of a single spectrum per sample. It is often referred to as 
chemical imaging, vibrational imaging, infrared imaging, or hyper-
spectral imaging. The actual images are obtained by selecting one or 
multiple parts of the spectrum for visualization in the spatial dimension 
of the sample, as schematically depicted in Fig. 2 under the corre-
sponding section. For protein-based biopharmaceutical characterization 
studies, NIR and MIR absorbance spectra are of interest as particular 
parts of the spectra have been empirically correlated to structural pro-
tein properties, such as secondary structural motifs [39–42]. In turn, the 
type and amount of structural protein properties allow for a distinction 
between different proteins as well as structural changes of a protein. 
Photon absorption in the NIR and MIR region of the electromagnetic 
region leads to vibrational transition, where energy is absorbed if the 
photon energy is equal to the difference in a vibrational state [16]. 
However, the key selection rule for IR absorption states that a photon 
will only be absorbed if the electric dipole moment of the molecule 
changes as a result of the vibrational motion [22]. This means that IR 
absorbance occurs for polar bonds and nonsymmetric vibrations. 
Absorbance in the MIR region generates information on atomic 
stretching and bending of fundamental vibrations (transition from the 
ground state to the first excited vibrational state), while absorbance in 
the NIR region provides information on overtone bonds (transition from 
the ground state to a second or third state) and combination bonds 
(vibration interactions of fundamental bonds). NIR absorbance spectra 
are often obtained by means of transmittance or (trans)reflectance 
detection modes [43,44] and absorption in the MIR region is obtained by 
means of the attenuated total reflectance (ATR) mode, because strong 
absorption is a limiting factor for MIR. The ATR mode uses a highly 
reflective element, which fully reflects the incident beam, resulting in an 
evanescent wave that interacts with the sample on top of the ATR 
element. The evanescent wave only interacts with a thin layer of the 
sample, thereby preventing absorption saturation [44]. Because of the 
different wavelength regions, MIR and NIR measurements have different 
strengths and weaknesses. A disadvantage of NIR is that the absorption 
bonds are 10–100 times weaker than the corresponding MIR bonds [44] 
and show largely overlapping absorption curves, which complicates 
band assignment and data interpretation. However, the low absorption 
coefficient in the NIR region can be also an advantage, as it allows for a 
higher penetration depth than MIR, which is desirable for thicker sam-
ples [45], solids [44], and measurements through glass [19]. Both MIR 
and NIR have the disadvantage that water bonds absorb strongly, as it is 
a polar molecule, and in the same range as protein-related bonds. MIR 
shows the strongest water bond absorption and is therefore most 
adversely affected by the dominant water signal [39,44]. 
In addition to absorbance, the NIR region is also used to capture 
inelastic Raman scattering. As mentioned in the Introduction, Raman 
scattering occurs when the incident photons interact with matter and 
scatter after exchange of energy. The selection rule that applies to 
Raman scattering is the change in polarizability of the molecule as a 
result of the vibrational motions and the energy that is exchanged is 
equal to the energy needed for the respective vibrational transition [19]. 
Thus, similar to NIR/MIR absorption, a change in vibrational state is the 
cause of the energy difference between the incident and scattered 
photon. However, Raman scattering is fundamentally different as it is a 
scattering event and only occurs if there is a change in molecular 
polarizability instead of the electric dipole moment for NIR/MIR photon 
absorption [22]. Due to this fundamental difference, Raman scattering 
occurs for symmetric stretching vibrations and results in the inefficient 
Raman scattering of polar molecules, such as water [44,46]. This means 
a relatively weak signal of water is obtained in a Raman spectrum, 
compared to NIR and MIR absorption [47]. Raman scattering is regarded 
as an alternative as well as a complementary source of property infor-
mation next to MIR and NIR absorbance because it provides structural 
information and has the ability to detect IR inactive bonds. 
Raman scattering occurs at a range of wavelengths, but several 
compounds fluoresce when illuminated with photons of short wave-
lengths and the subsequent fluorescence intensity often overpowers the 
Raman signal [19]. Using excitation at 785, 830, and 1064 nm (NIR 
region), the wavelengths are long enough to minimize such fluorescence 
effects. However, longer wavelengths for excitation decrease the effi-
ciency of Raman scattering as scattering intensity is inversely propor-
tional to the fourth power of the wavelength [16]. Another approach to 
minimize fluorescence is the use of pulsed excitation where one can 
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benefit from the different time scales of fluorescence or Raman scat-
tering events [47]. The fundamental difference between these phe-
nomena results in a different emission timescale, namely 10− 8–10− 9 s for 
fluorescence compared to < 10− 15 s for scattering [18]). 
2.5. Far infrared (30 μm-1 mm) 
Absorbance in the far-infrared (FIR) region of the electromagnetic 
spectrum is used for chemical imaging in a similar fashion as mentioned 
in the previous section on NIR and MIR. The so-called terahertz (THz) 
region is often applied, which approximately ranges from 10 µm to 1 mm 
(0.3–30 THz). The wavelength in the FIR region is longer compared to 
NIR and MIR, which causes the incident photons to have a lower energy. 
The light in this region is therefore predominantly influenced by inter-
molecular motions or crystalline lattice vibrations [48]. Spectroscopic 
applications using the FIR region are able to distinguish between 
different protein quaternary structures and higher-order structures, as 
well the hydration level in proteins [48,49]. Imaging in the FIR region 
has advantages over the other IR imaging approaches, as FIR light can 
penetrate samples up to 3 mm [48], meaning it allows one to obtain 
spectral data from within the sample, without destroying the sample. 
3. Image processing and analysis 
Once an image is captured by the acquisition device, the raw data 
requires further processing before the information content can be 
analyzed and interpreted. Depending on the application, several steps 
are involved during image processing and analysis, namely pre- 
processing, segmentation, description, and interpretation [50]. These 
steps are schematically depicted in Fig. 3. 
Pre-processing of data is used to improve data quality and prepare 
extraction of information, such as noise reduction or contrast enhance-
ment. The improved image is further processed by means of segmenta-
tion. Segmentation aims to obtain solely the information that is of 
interest for the respective application. This can entail spatial segmen-
tation, by extracting information from a part of the image (left icon in 
Fig. 3 at the Segmentation section), or by characteristic segmentation, 
such as the extraction of a specific color level (right icon in Fig. 3 at the 
Segmentation section). The segmented information is passed on to the 
description step. Here, imaging-based features are extracted that quan-
tify the information in the image. For example, this involves information 
extraction on lines, objects, or texture. Quantification is done by 
extracting, for instance, pixel counts, pixel intensity, color levels, or a 
change in any of these properties over time or in their spatial di-
mensions. The final step, interpretation, uses the extracted features to 
fulfill the set-out task. To illustrate the last step, the schematic overview 
in Fig. 3 shows the identification of objects and the ratio between certain 
colored objects. The conversion of the imaging-based features to inter-
pretable results is often supported by multivariate data analysis and (un) 
supervised machine learning approaches. An extensive overview of 
multivariate image analysis for both spectral and visible light images is 
provided by Prats-Montalban et al. [51]. 
4. Imaging applications 
The following sections cover how imaging with different parts of the 
electromagnetic spectrum is currently utilized for protein-based bio-
pharmaceutical formulation characterization and development studies, 
sectioned per (bio)physical property. This review covers (bio)physical 
properties that are captured by means of imaging and that are applied 
for the most common protein-based biopharmaceutical formulation 
formats, namely liquid, freeze-dried, and spray-dried formulations. An 
overview of the content of this review is listed in Table 1. Table 1 in-
cludes the applications, the employed imaging methods, the corre-
sponding electromagnetic spectrum, as well as the main information 
that is obtained with each method. 
4.1. Subvisible particle characterization 
Particles are defined as a minute piece of matter with defined 
physical boundaries [145] and can be divided into four quantitative 
size-based categories, namely > 100 μm, 1–100 μm, 0.1–1 μm (submi-
cron particles), and < 100 nm (nanoparticles) [146]. The first category 
is often referred to as visible particles, while the latter 3 categories are 
often referred to as subvisible particles, which spans from protein 
monomers to soluble and insoluble protein aggregates. Particle forma-
tion in protein-based biopharmaceutical products is, on the one hand, an 
undesired phenomenon, as inherent drug product-related particles such 
as protein aggregates can cause adverse immune responses [147] and 
intrinsic or extrinsic particles, such as silicone droplets or lint, may 
induce proteinaceous particle formation [148,149]. On the other hand, 
particle formation can also be a goal of processing and formulation, for 
example when developing a crystalline or dry powder product. In the 
following subsections, imaging-based analytics for subvisible particle 
detection and characterization in liquid and solid formulations will be 
covered. Imaging-based techniques for visible particle characterization 
are part of the Section 4.2: Phase Transition in Liquid Formulations. An 
overview of the discussed image-based analytical techniques for each 
subsection is shown in Fig. 4, including a representative image for each 
discussed technique. 
4.1.1. Subvisible particle characterization in liquid formulations 
For liquid formulations, formation of subvisible particles is an un-
desired phenomenon and is considered a critical quality attribute (CQA) 
on its own [52,150,151]. There is not a single analytical technique that 
captures all aforementioned size ranges, and different techniques are 
therefore employed to cover different size ranges [152]. Regardless of 
the size range, analytical techniques employed for subvisible particle 
characterization should be able to detect, identify, and quantify particles 
[153]. Non-imaging-based techniques used for subvisible particle 
detection include, but are not limited to, dynamic light scattering (DLS), 
light obscuration (LO), and asymmetrical flow field flow fractionation 
[154–156]. Non-imaging-based techniques are able to generate infor-
mation on particle size, its distribution, and concentration, but often 




















Fig. 3. Schematic overview of general steps performed during image process-
ing and image analysis. 




Overview of literature per application and the employed electromagnetic spectrum (EMS) section.  
Application EMS section Method Information content References 
Sub-visible particle characterization 
In liquid formulations 
Visible light FIM Size (>0.75 µm [52–54]) 
Morphology 
[55–61]  
BMI Size (>2 µm [61]) [62,63] 
IFC Size (0.1–100 µm [64]) 
Composition and compound distribution 
[64–66] 
NTA Size (30 nm − 1 µm [67]) [67,68] 
In solid formulations Bright field Size (>10 µm [69,70]), Morphology [69–73] 
Digital holography Size (20 µm – 3 mm [74]), Morphology [74] 
Phase transitions in liquid formulations UV UV-light imaging Size, morphology, composition [75–77] 
Visible light Bright field [78–87] 
Stereo imaging [88] 
Fluorescent labeling [89–96] 
Cross polarized light Crystal presence [97–99] 
NIR SONICC Crystal identification [100–102] 
MIR ATR-FTIR Structural state of proteins 
Protein species 
[103,104] 
Conformational stability MIR (ATR-)FTIR Structural state of proteins [105–107] 
Drying effects 
Process parameters 




Visible light SDD Droplet geometry [117–119] 
Residual moisture content and homogeneity NIR Chemical imaging Moisture content 
Compound distribution 
[120,121] 
NIR SDD [122–124] 
Raman Compound distribution [125]  
Cake appearance Visible light Bright field Cake height, glassiness, uniformity, color [126,127] 
Freeze/thaw effects Visible light Bright field Protein long-term stability 
Freezing and thawing temperature 
[128–133] 
MIR Thermography Sample and ice nucleation temperature 
Ice crystal distribution 
[129,134–136] 
NIR Raman Compound distribution [137,138] 
Protein cloud-point temperature Visible light Bright field Sample turbidity [129,130,139] 
Surface tension Visible light ADSA Droplet shape [140–144] 
Abbreviations 
EMS: electromagnetic spectrum, FIM: flow imaging microscopy, BMI: backgrounded membrane imaging, IFC: imaging flow cytometry, NTA: nanoparticle tracking analysis, UV: ultraviolet, NIR: near infrared, MIR: mid- 
infrared, ATR-FTIR: attenuated total reflection Fourier transform infrared, SONICC: second order nonlinear optical imaging of chiral crystals, SDD: single droplet drying, ADSA: axisymmetric droplet shape analysis 
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Most imaging-based techniques have the advantage to be able to 
quantify particle characteristics and identify the particles as well. 
A widely applied imaging-based technique is flow imaging micro-
scopy (FIM), which captures visible light images of a liquid sample as it 
flows through a cell and it allows for particle characterization down to 
0.75 µm [52–54]. Most recent studies employing FIM for subvisible 
particle characterization focus on data processing and data evaluation 
automation, and some will be highlighted in this section to indicate the 
variety of approaches and applications. One of these studies was able to 
use FIM data to separate drug formulations that led to severe adverse 
reactions and formulations that did not, based on differences in particle 
morphology properties, such as diameter and circularity [56]. In other 
studies, classification algorithms based on FIM data were developed to 
accurately distinguish between protein and silicon particles [57], or 
silicon and non-silicon particles [58]. FIM data in combination with 
advanced and automated analysis is also used to identify the root cause 
of particle formation. For instance, recent applications of FIM data 
coupled to advanced classification algorithms showed the ability to 
elucidate the stressor origin, such as agitation or freeze/thaw stress, of 
particles found in pre-filled syringes [59] or monoclonal antibody for-
mulations [60]. Yet another study presented how supervised machine 
learning of convolutional neural networks allows for the classification of 
process conditions or stress states of subvisible particle from FIM data 
[61]. Not only individual particle images can be classified, also particle 
populations have been used. In this concept, a particle population is 
compared to a baseline particle population to detect deviations and to 
establish the root cause of the found deviation [55]. Representative 
images of this study are shown in Fig. 4a. The diversity of angles for data 
evaluation and application reflects the strengths of FIM for subvisible 
particle characterization and how it supports further understanding of 
subvisible particle formation. 
A more recently developed imaging-based analytical technology for 
subvisible particle characterization is backgrounded membrane imaging 
(BMI), where visible light images are taken of a membrane before and 
after a liquid sample is dispensed on top and filtered through the 
membrane. The empty membrane image is used for background sub-
traction, thereby elimination background information and thus 
enhancing particle detection. BMI was developed to overcome limita-
tions encountered for LO and FIM, such as cleaning issues, a low sample 
throughput, and large sample volumes [62]. Two recent studies per-
formed comparability experiments with BMI, LO, and FIM, which 
highlighted the higher sample throughput (96 samples), low sample 
volume requirement (only 20 µL instead of several 100 µL), and ability 
for particle detection despite an almost similar refractive index of the 
particle and its surroundings when using BMI [62,63]. An image ob-
tained with BMI is shown in Fig. 4b. Even though BMI has shown these 
advantages, it was stated that BMI still requires further development to 
become competitive when it comes to generating morphological infor-
mation and the detection of particles with homogeneous properties, 
such as polystyrene standard particles [62,63]. 
Fluorescent labeling and subsequent imaging, referred to as imaging 
flow cytometry (IFC), is also applied for subvisible particle detection. It 
was stated that IFC is a simpler method for protein identification 
compared to FIM (via dyes instead of particle characteristics), while it 
also remains high-throughput and automated [65,66]. Similar to FIM, a 
recent study showed that IFC is able to accurately classify and size sil-
icon droplets and protein aggregates [64]. Moreover, this study reported 
on how IFC provides a visual representation of proteins agglomerating 
on the silicon droplet surface [64]. A representative IFC image is shown 
in Fig. 4c. Nevertheless, IFC is dependent on a fluorescent signal, which 
requires additional sample preparation and potential product interfer-
ence, and this technique cannot provide data on particle characteristics. 
A fundamentally different imaging approach to identify nano- and 
submicron particles is nanoparticle tracking analysis (NTA, detection 
from 0.03 µm to 1 µm) [67,68]. During NTA, cameras are used to track 
the Brownian motion of particles by means of laser illumination. The 
Brownian motion is used to determine the diffusion coefficient, which, 
in turn, is used to calculate to the hydrodynamic radius via the modified 
Stokes-Einstein equation [157]. An example of a NTA image is presented 
in Fig. 4d. Even though this technique was found to be suitable for 
protein aggregate detection [67,68,158], NTA solely provides informa-
tion on the number-based size distribution as well as a semi-quantitative 
particle concentration, and not morphological particle characteristics. 
Moreover, the accuracy of NTA was shown to be dependent on the 
number of detected particles [67], camera settings [159], and the 
presence of large particles, which can adversely influence the mea-
surement [158]. 
4.1.2. Subvisible particle characterization in solid formulations 
Subvisible particle characterization for solid formulations is appli-
cable for freeze- and spray-dried formulations. Dried particles for pul-
monary drug delivery should lie between 1 µm and 5 µm (depending on 
the application) [160,161] and representative work focused on 
enhancing biopharmaceutical storage stability by spray-drying report a 
Fig. 4. Imaging examples for sub-visible particle characterization in liquids (upper row) and in solids (bottom row). The shown images are obtained with (a) flow 
imaging microscopy (FMI) [55], (b) backgrounded membrane imaging (BMI) [62], (c) imaging flow cytometry (IFC) [64], (d) nanoparticle tracking analysis (NTA) 
[67], (e) digital holography [74], and (f) bright field imaging [70] . 
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particle size between approximately 1 µm to 30 µm [162,163]. Thus, the 
obtained dry powder particles are considered to fall in the category of 
subvisible particles. 
Particle size, distribution, and morphology are of importance, as 
these properties determine pulmonary drug product performance [164] 
or reconstitution behavior of dried products [165,166]. In addition, the 
pore structure of freeze-dried particles is evaluated as pore size regula-
tion can optimize the drying steps of the process [167]. These particle 
properties are influenced by process parameters, such as drying air 
temperature for spray-drying or freezing rate for freeze-drying [168], 
and formulation composition, such as feed concentration [169]. Re-
ported non-imaging-based analytical techniques used for the determi-
nation of particle size and distribution can be similar to liquid 
formulations, such as laser diffraction [71]. However, non-imaging- 
based analytics suffer from similar disadvantages too, such as the 
inability to obtain information on particle morphology. An imaging- 
based technique used to assess the particle morphology after spray- 
drying is visible light microscopy [69–73]. A visible light image of a 
spray-dried particle is shown in Fig. 4f. However, the applicability of 
light microscopy for spray-drying studies is limited by the depth of field 
[74]. Digital holography imaging was applied in a field other than 
biopharmaceutical formulation research for droplet size (down to 20 
µm) and droplet size distribution measurements have shown to improve 
depth of field limitations [74]. An example of such a digital holography 
image is shown in Fig. 4e. Though the depth of field is improved with 
digital holography, the application for biopharmaceutical formulation 
research is not established. In addition to the depth of field, a more 
restricting factor for visible light imaging is resolution, as the mentioned 
particle sizes (1–30 µm) are near or below its detection limit [156]. To 
overcome the resolution limitation, scanning and transmission electron 
microscopy (SEM/TEM) are often used to provide (morphological) 
particle information of spray and freeze-dried particles [170]. Although 
SEM and TEM are imaging techniques, the techniques are fundamentally 
different from the imaging techniques discussed in the review (SEM and 
TEM use electron beams instead of photon beams) and are therefore 
considered out of scope of this review. 
4.2. Phase transitions in liquid formulations 
This section on phase transitions in liquid formulations covers im-
aging approaches used for the evaluation of protein phase diagrams, a 
methodology used to assess protein phase behavior as a function of 
varying conditions, such as pH, additives, and product concentration 
[171]. This experimental approach is employed to identify crystalliza-
tion conditions [172–174] and generate an understanding of protein 
phase behavior in liquid formulations [78,175]. Imaging is the main 
analytical technique to evaluate protein phase diagrams [176], where 
crystallization studies focus on finding protein crystals (Fig. 4D) and 
protein phase behavior studies focus on the identification of any type of 
phase transition, such as liquid–liquid phase separation or skin forma-
tion [177,178]. Similar to subvisible particle characterization, the 
presence of non-protein particles, such as dust, is also of interest for both 
crystallization and phase behavior studies. Thus, this section includes 
image-based techniques applicable for visible (non–)protein particle 
characterization in liquid formulations, but is not explicitly defined as 
such, as not all protein phase diagram results are composed of visible 
particles. A set of selected examples of images for different techniques 
discussed in this section are shown in Fig. 5. 
Visible light is the most widely employed light source to evaluate 
protein phase diagrams (Fig. 5e). Adjustments in all steps of the image 
analysis workflow are explored to optimize and automate protein phase 
behavior evaluation. Automated image acquisition was achieved by 
implementation of robotic imaging systems and the use of liquid 
handling stations increased the sample throughput up to 1536 well 
plates [78,79,179]. Self-built multi-well plate imaging equipment was 
presented as an economic optimization, to facilitate a wider imple-
mentation of protein phase diagram imaging systems [80,81,83]. In-
formation retrieved by image acquisition is expanded by increasing the 
acquisition frequency, where data extraction from visible light imaging 
was performed over the entire time course of an experiment, instead of 
solely endpoint images [84,86,87]. 
Most studies aiming to advance protein phase behavior screenings 
report on image acquisition hardware adjustments, where the imaging 



















a. UV-light imaging c. ATR-FTIRb. SONICC
e. Bright field f. Cross polarized g. Stereo imagingd. Fluorescent label
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Fig. 5. Imaging examples for detection of phase transitions in liquid formulations. The shown images are obtained with (a) UV-light imaging (image obtained from 
own database), (b) second order nonlinear optical imaging of chiral crystals (SONICC) [101], (c) attenuated total reflection Fourier transform infrared (ATR-FTIR) 
chemical imaging [103], (d) fluorescent labelling imaging [89], (e) bright field imaging (image obtained from own database), (f) cross-polarized light imaging [101], 
and (g) stereo imaging [88]. 
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example, light polarization was used to specifically find crystallized 
proteins, as crystals are birefringent [97–99]. In Fig. 5f an image ob-
tained with light polarization is shown. Another example is the use of a 
two-camera configuration to perform stereo imaging of protein crystals 
in the visible light range. This allows one to characterize protein crystal 
properties, such as face growth rate or surface area, via a three- 
dimensional image [88,180]. An example of a stereo-image is shown 
in Fig. 5g. Despite the ability to obtain three dimensional information on 
crystals, visible light stereo imaging is not widely applied for phase 
transition studies. This may be a result of the complex computational 
steps required to perform data evaluation or the sensitivity of the 
configuration [180]. The implementation of different light sources 
covers almost the entire range of the electromagnetic spectrum dis-
cussed in this review. UV light is used to distinguish between protein and 
non-protein phase states, by making use of intrinsic protein fluorescence 
[76,77]. A UV-image of crystallized lysozyme is shown in Fig. 5a. Low- 
cost configurations were demonstrated for UV-based imaging, such as 
the on-chip UV holographic crystal imaging platform developed by 
Daloglu et al. [75]. Even though the UV-range is most often used to 
identify proteinaceous material, intrinsic protein fluorescence in the 
visible light range was demonstrated as well [85]. However, among 
other disadvantages, the degree of UV-auto-fluorescence differs between 
proteins, and in some cases auto-fluorescence is even non-existing 
[181]. This complicates the development of a general applicable 
approach for protein phase behavior screenings. One of the solutions for 
the auto-fluorescence problem is the use of trace fluorescence labeling of 
the protein (extrinsic fluorescence), which allowed for a clear distinction 
between protein molecules bound to the fluorescent compound and the 
other solution components [89,90,93,96]. An image obtained with 
extrinsic fluorescence is shown in Fig. 5d. Miniaturization and simpli-
fication of extrinsic fluorescent imaging was also demonstrated, such as 
a chip-based approach [91] and configurations using mobile phones as 
acquisition device [92,94,95]. Even though fluorescent labeling sim-
plifies protein identification, addition of fluorescent labels is often un-
desired due to additional sample preparation steps. 
Light sources using longer wavelengths than visible light were suc-
cessfully implemented as well. A relatively new technique is called 
second order nonlinear optical imaging of chiral crystals (SONICC), 
which uses a 800 nm light source [100–102]. An image obtained with 
the SONICC technique is shown in Fig. 5b. This technique showed useful 
for crystal identification but it did not provide any additional 
information for other possible phase states. Another technique in the IR 
range, ATR-Fourier Transform IR (ATR-FTIR) chemical imaging, was 
also shown as a valuable tool [103,104]. This technique uses the protein- 
specific amide II band absorbance in the ATR-FTIR spectrum to identify 
proteins, up to six samples at once (shown in Fig. 5c) [103]. The 
chemical information could potentially distinguish between different 
structural states of a single protein species or between different protein 
species, which could be useful to identify targeted phase transitions of 
complex protein mixtures. The last section of the electromagnetic 
spectrum that falls within this review is the THz range. The THz range 
has not been applied yet for the purpose of screening protein phase 
behavior as a function of different environmental conditions, but it is 
applicable to determine polymorphic crystal forms [48]. This informa-
tion could be a useful feature to distinguish between different crystal 
types. 
Next to image acquisition, a route for phase state identification 
improvement can also be found via the pre-processing, segmentation, 
and description step in the image analysis workflow. A concise summary 
of work reporting on different approaches for each step in the image 
analysis workflow can be found in the Chapter 4 of the book Data An-
alytics for Protein Crystallization by Pusey and Aygün [182]. What the 
authors of this review would like to emphasize in addition to the sum-
mary provided by Pusey and Aygün, is the general trend towards tar-
geted human interpretation. Targeted human interpretation means that 
advanced computational approaches are used to minimize subjective 
data evaluation by operators and/or scientists, but still allow room for 
interpretation to gain fundamental insights. This trend becomes evident 
from the development of pattern recognition algorithms [183] and data- 
dependent descriptors [184], instead of describing an image by (enor-
mous [185]) feature sets, obtained from global images, local sections 
[186], or even individual pixels [187]. This is also shown by the 
exploration of different light source combinations instead of using just 
one light source to capture all characteristics [84,188,189]. Lastly, it has 
become apparent that a perfect protein phase state classification algo-
rithm is hard to come by. Thus, by understanding the added value of 
(multiple [93,190]) classifiers, one can make proper use of the proba-
bility of correct protein phase state classification based on imaging data, 
for example by directing human interpretation to low probability clas-
sifications [84]. 
Fig. 6. Imaging examples for the evaluation of drying effects. Images are obtained with (a) chemical imaging based on Raman scattering [120], (b) single droplet 
drying with bright field imaging [118], (c) thermography [163], (d) single droplet drying chemical imaging based on Raman scattering [123], and (e) bright field 
imaging [127]. Image (a) and (d) are representative imagines to evaluate residual moisture and compound heterogeneity, (b) and (c) are representative for process 
parameter evaluation, and image (e) for cake appearance evaluation. 
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4.3. Drying effects 
Protein-based biopharmaceutical products are dried to enhance 
shelf-life [162,191–193] or to obtain a biopharmaceutical formulation 
applicable for pulmonary drug delivery [160,168,194]. Dry powder 
biopharmaceuticals are mainly produced by means of freeze-drying 
(also known as lyophilization) [195,196]. This procedure includes 
three steps, namely (1) freezing, (2) sublimation of ice (primary drying) 
and (3) desorption of water (secondary drying) [192]. Freeze-drying is 
found to be relatively expensive due to its time-consuming and batch- 
based operations, and the capital investment for the cryogenic facil-
ities. The second most often applied drying method, spray-drying, is 
seen as an alternative approach as it can overcome the disadvantages 
mentioned for freeze-drying [197]. Spray-drying produces dry powder 
by atomizing a liquid feed into droplets within a hot medium, such as 
steam, resulting in the evaporation of the solvent from the droplets 
[198]. However, any type of water removal processing step can induce 
protein destabilization [192]. Drying may impair conformational, 
colloidal, and chemical stability, and it may result in the removal of 
functional water molecules [196,199–201]. To ensure a stable, safe, and 
functional end product, the influence of drying process parameters on 
product quality needs to be evaluated during the development of dry 
powder biopharmaceutical formulations. In this section, the role of 
imaging during the drying step of freeze and spray-drying is presented. 
The role of imaging during the freezing step of freeze-drying will not be 
covered here, as this is covered in Section 8: Freeze/Thaw Effects. The 
following subsections present imaging-based approaches used to extract 
information on critical drying process parameters. In addition, three 
product quality attributes will be discussed, namely residual moisture, 
compound homogeneity, and freeze-dried cake appearance. A selection 
of images obtained with techniques discussed in this section are shown 
in Fig. 6. 
4.3.1. Drying process parameters 
One of the critical processing parameters for freeze- and spray-drying 
is temperature. Commonly employed non-imaging-based temperature 
measurement techniques for freeze-drying are thermocouples and 
resistance temperature detectors, which are invasive and require a 
subjective selection of a few samples to be measured [202]. Thermal 
imaging is non-invasive and it offers spatial temperature readings, a 
characteristic applicable for analyzing multiple samples at once. In 
addition, thermal imaging can simultaneously determine the tempera-
ture variations within a sample. The first implementation of a thermal 
camera on the outside of a freeze-drying chamber was described by 
Emteborg et al., which resulted in the quantification of temperature 
variations between formulation vials during the primary drying step 
[108]. Thermography also facilitated the estimation of kinetic freeze- 
drying parameters, where a study by Lietta et al. reported on the esti-
mation of the end of primary drying (sublimation), the heat transfer 
coefficient, and the resistance of the dried product to vapor flux [109]. 
Not only drying process parameters were extracted by means of imaging, 
Colucci et al. showed how to use thermal and visible light imaging to 
determine temperature deviations in the entire drying process 
[113,114]. Work was also reported on developments for the computa-
tional side of image analysis, where a real-time data extraction workflow 
for enhanced vial detection and image segmentation based on thermo-
graphic data was presented [112]. 
The implementation of a thermal camera enhanced process under-
standing, but it also led to discussion on camera placement. A freeze- 
drying chamber often consists of multiple shelves and multiple vials 
per shelve. Measuring from the top of the chamber results in the loss of 
information from the shelves below the top shelf, while measurements 
from the side do not capture vials at the back of the chamber. Thus, 
thermography is able to perform noninvasive temperature measurement 
for more samples than non-imaging-based techniques, it is not able to 
account for all nonuniformity due to the technical limitations of the 
drying equipment. To overcome nonuniformity of batch-freeze-drying 
(among other limitations), continuous spin freeze-drying was devel-
oped [203]. This freeze-drying method facilitates vial-per-vial evalua-
tion and was used in combination with thermography in a study 
performed by Van Bockstal et al.. This work resulted in the identification 
of the primary drying end point and mass transfer parameters useful 
during product and process development [110]. 
For spray drying, a recent study showed how thermal imaging was 
implemented to monitor the spraying nozzle temperature. The respec-
tive work visualized temporal and spatial nozzle temperatures (Fig. 6c), 
which led to identification of the root cause of lysozyme’s reduced ac-
tivity after spray-drying [163]. Such a study requires a benchtop or in-
dustrial scale spray dryer, which is not ideal for (early stage) 
characterization studies due to the required amount of protein material. 
To minimize material consumption, spray-drying process parameters are 
often evaluated via single droplet drying (SDD) experiments. In SDD 
experiments a single sessile, free flight, or levitating droplet is produced 
and dried over time to mimic spray-drying conditions [118,204]. A 
representative image of a sessile drop is shown in Fig. 6b. The selection 
of a particular SDD method affects the observed kinetics, where each 
SDD method has its own advantages and disadvantages [205]. Even 
though SDD is applicable to retrieve an understanding of spray-drying 
on a benchtop or industrial scale, particle size and particle processing 
time obtained via SDD experiments is not identical to large scale spray- 
dryers. Thus, information obtained on kinetics and morphology should 
solely be seen as an additional source of fundamental insights 
[205,206]. Despite the deviations between SDD and larger scale spray 
drying, process parameters for spray-drying have been modeled based 
on a SDD data. Single droplet thermographic measurement have been 
performed [115,116], but also visible light imaging was applied for 
drying process understanding and modeling [117,118]. Visible light 
imaging was used to extract the geometry of drying droplets over time 
and employed to model the drying process, where the resulting models 
were able to predict post-spray-drying enzyme activity [118,119]. It 
would be interesting for the field of biopharmaceutical formulation 
research to determine the applicability of such SDD-based models for 
protein stability prediction. 
4.3.2. Residual moisture content and homogeneity 
It has been shown in multiple studies that the required amount of 
residual moisture to ensure product stability is protein-specific and, 
thus, the lowest amount of residual moisture is not always desired 
[207,208]. Moreover, the distribution of residual moisture is also of 
interest, as an uneven distribution of the residual moisture is a sign of 
local overdrying, thereby creating a possible destabilizing environment 
in overdried regions [209]. Thus, to determine the quality of the dry 
powder and the product itself, it is important to measure the residual 
moisture content, moisture homogeneity as well as the protein state and 
homogeneity. 
Examples of non-imaging-based techniques to determine the residual 
moisture after drying are Karl Fischer titration [210] or thermog-
ravimetry (recording mass as a function of temperature) [211], both 
destructive and invasive methods. This led to the implementation of IR 
spectroscopy as a noninvasive alternative [212,213], where water 
interference in the IR region is considered an asset instead of a nuisance, 
as is the case when studying protein structural elements with IR spec-
troscopy. Imaging-based techniques were derived from the spectro-
scopic approaches to introduce the spatial information in addition to the 
spectral data. The study by Brouckeart et al. mentioned in Section 7.1, 
which employed spin freeze-drying and thermography, additionally 
implemented chemical imaging in the NIR region to determine the 
moisture content and compound homogeneity for mannitol-sucrose 
formulations [120]. A representative image is shown in Fig. 6a. NIR 
imaging was also used to determine sugar crystallization in addition to 
residual moisture for mannitol/sucrose/lysozyme or bovine serum al-
bumin mixtures after freeze-drying and after storage of the freeze-dried 
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formulations [121]. A study focused solely on product distribution by 
chemical imaging based on Raman scattering showed the influence of 
glycerol on lysozyme/trehalose formulations during freeze-drying 
[125]. For spray dried formulations, SDD experiments used Raman im-
aging to determine the residual moisture and homogeneity of dextran/ 
sucrose mixtures within the spray dried particle [122]. SDD chemical 
imaging has also been employed to study the distribution of different 
protein/sugar formulations, such as lysozyme/mannitol [124] and 
bovine serum albumin/lactose (Fig. 6d) [123]. Information obtained 
with chemical imaging on residual moisture content as well as moisture 
and product distribution generates a broader understanding of the in-
fluence of formulation parameters on particle engineering. This 
knowledge can be applied to enhance product stability and product 
functionality via formulation optimization on a particle level. 
4.3.3. Cake appearance 
After freeze-drying, the resulting dry powder product is referred to as 
the cake. The appearance of the cake is important as it reflects the 
quality of the freeze-drying process and it is considered a critical quality 
attribute by the health authorities [214]. Undesired cake properties are, 
for instance, cake collapse (leading to a longer reconstitution time) and 
meltback (indicating an incomplete sublimation step) [215]. Visible 
light imaging evolved from the traditional visual inspection as an 
imaging-based analytical approach for cake appearance evaluation. 
Similar to crystallization and phase transition studies, cake appearance 
evaluation has long been a subjective approach, performed by operators 
and/or scientists. This initiated the development of machine learning 
approaches that are able to evaluate the cake appearance, and thus its 
quality. A high-throughput image analysis algorithm based on visible 
light images was developed by Trnka et al. to automatically evaluate 
cake collapse, glassiness, uniformity, and color [126,127]. A represen-
tative image is shown in Fig. 6e. The workflow developed by Trnka et al. 
is applicable for formulation design screening purposes only, as freeze- 
drying and subsequent image analysis was performed in multi-well 
plates and not in formulation vials. 
Visible light imaging is fast and relatively simple to implement, but 
its main limitation is that visible light imaging only evaluates the 
exterior of the cake. Haeuser et al. published work comparing a variety 
of imaging-based techniques to evaluate the applicability for capturing 
the interior of the cake [216]. For this, Haeuser et al. used visible light 
imaging and microscopy, three-dimensional laser scanning, scanning 
electron microscopy, and microcomputed tomography (µCT) to evaluate 
freeze-dried formulations with a cake volume between 5.25 cm3 and 
8.43 cm3 and a diameter of approximately 28 mm. Out of these tech-
niques, µCT was highlighted as a imaging technique with potential for 
the application of cake appearance, as it is able to perform non-invasive 
qualitative and quantitative measurements through glass [216,217]. 
However, this technique falls outside of the electromagnetic spectrum 
range discussed in this review and will therefore not be further 
discussed. 
4.4. Freeze/thaw effects 
Freezing and thawing are a part of biopharmaceutical production 
processes, where it is used for intermediate holding during processing, 
transport, and long-term storage of liquid formulations. However, 
freeze/thaw (F/T) cycles can affect proteins’ conformational stability 
resulting in cold denaturation [218] or denaturation at the ice interface 
[219], thereby compromising protein function, efficacy, and product 
safety. Moreover, freeze concentration during F/T cycles may also 
change the environmental conditions in such a way that it induces 
conformational, colloidal, or chemical instability [220]. Formulation 
composition and F/T processing parameters, such as cooling rate or 
minimum temperature, are optimized to minimize these effects. On the 
right side of Fig. 7 representative images are shown which were used to 
study freeze/thaw effects. 
Studies performed by Wöll et al. employed visible light imaging for 
high-throughput and low volume screening of long-term stability effects 
induced by F/T cycles as a function of process parameters, such as 
cooling rate and F/T cycle number, and formulation parameters, such as 
buffer pH and salt concentration [131–133]. Visible light imaging is also 
able to detect temperature-induced phase transitions during a F/T cycle. 
Fig. 7. Imaging examples for the evaluation of the 
(a) protein cloud-point temperature, (c) surface 
tension, (e) conformational stability, and (b, d, f) 
freeze/thaw effects. Images are obtained with (a, b) 
bright field imaging (images obtained from own 
databse), (c) axisymmetric droplet shape analysis 
(ASDA) with bright field imaging [143], (d) chem-
ical imaging based on Raman scattering [138], (e) 
attenuated total reflection Fourier transform 
infrared (ATR-FTIR) chemical imaging [105], and 
(f) thermography [135].   
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The pixel intensity difference between the starting image and subse-
quent images captures during a F/T cycle showed distinct points in the 
intensity difference-temperature profile, of which two were traced back 
to freezing and thawing points of lysozyme formulations (Fig. 7b) [130]. 
A comparable imaging approach extracted the mean pixel intensity of 
visible light images to determine the freezing and thawing temperature 
during cryopreservation of cells, which may be of interest for cell-based 
biopharmaceutical products [128]. Determination of these transition 
points does not yield direct information on product quality, but corre-
lation studies that link thermal transition points to stability or func-
tionality allows one to adjust F/T process parameters and formulation 
composition accordingly. 
In addition to freezing and thawing temperature, there are other 
characteristics of interest during freezing of protein-based bio-
pharmaceuticals that are extractable via imaging, such as the ice 
nucleation temperature and ice crystal distribution. Ice nucleation is the 
spontaneous formation of ice crystals in super-cooled solutions, which 
affects the ice crystal distribution and subsequently the drying time and 
product quality during freeze-drying processes [165]. Thermography is 
able to detect ice nucleation as it is an exothermic reaction, which results 
in a sudden increase of temperature up to the equilibrium freezing 
temperature of the sample, where the difference may lie in the order of 
magnitude of ten degrees Celsius [167]. The ice crystal distribution can 
be determined directly with imaging, via techniques such as scanning 
electron microscopy [170] and micro-computed X-ray tomography 
[217]. However, these methods fall outside the scope of this review. 
Imaging techniques that fall within the range of this review facilitate 
only an indirect approach to estimate the ice crystal distribution. The 
estimation of the ice crystal distribution is generated via empirical and/ 
or mathematical models based on process parameters [221]. Colluci 
et al. employed thermography to capture temperature profiles within 
the frozen product and freezing front rates (Fig. 7f). This information 
was used to estimate the ice crystal size distribution at the end of the 
freezing step of the freeze-drying process [134,135]. Thermography has 
also been used to adjust computational fluid dynamic simulations [136]. 
These simulations are employed to predict the temperature and solute 
concentration development in sample containers during freezing. The 
solute distribution within frozen samples during freeze-drying has also 
been studied with Raman imaging. Raman images were visualized ratios 
between three components, namely ice, lysozyme, and sugar (sucrose 
and trehalose), which was used to elucidate the stabilizing effects of 
these sugars during freeze-drying [137,138]. A representative Raman 
scattering-based image is shown in Fig. 7d. 
4.5. Conformational stability 
Conformational stability refers to the structural stability of the folded 
protein molecule, which is often monitored during characterization 
studies. This is done as structural instability can lead to loss of product 
functionality or it can induce adverse immune reactions. One of the 
biophysical properties that represents conformational stability is the 
melting temperature (TM), where structural unfolding of a protein 
molecule is monitored over a temperature gradient as a function of 
different environmental factors, such as pH or osmolality [222]. The 
differences in temperature at which unfolding occurs allows one to 
interpret the relative degree of conformational stability. Conformation 
stability can also be monitored without a temperature gradient. In such 
experiments, proteins’ secondary structure motifs are identified and 
compared between different formulation parameters. Examples of 
commonly applied non-imaging-based techniques to monitor confor-
mational stability are DLS [223,224], dynamic scanning fluorescence 
(DSF) [225], circular dichroism (CD) [226], and Raman [227] or IR 
spectroscopy [228]. Imaging-based assessment of conformational sta-
bility is done with chemical imaging, allowing one to perform dynamic 
measurements and to distinguish and quantify different proteins and 
mono/multimeric protein species, which cannot be done with light 
scattering and fluorescence techniques. Raman and IR spectroscopy also 
possess these properties, but chemical imaging has the ability to capture 
multiple samples in one image and to visualize the species-distribution 
within the sample as a result of the spatial dimension. 
The first application of chemical imaging to investigate conforma-
tional stability of monoclonal antibodies was shown by Boulet-Audet 
et al., where monoclonal antibodies were investigated as a function of 
a multitude of environmental factors in a high-throughput manner 
(twelve samples per measurement) [105]. A representative image is 
shown in Fig. 7e. A similar imaging throughput was reached by De 
Meutter et al., where protein microarrays were used to analyze the 
secondary structure by means of chemical imaging for a multitude of 
proteins [106]. Another study employed ATR-FTIR imaging to deter-
mine structural differences between monoclonal antibody species in the 
bulk solution and precipitated monoclonal antibodies (six samples per 
measurement) [107]. Up until this moment, there are only a few 
chemical imaging studies performed to assess conformational stability 
for biopharmaceutical formulations, but examples for small molecules 
[229] and polymers [230] exist. Nevertheless, the reported work on 
biopharmaceutical-relevant proteins illustrates the detailed and valu-
able spatial information that chemical imaging can bring to the field. 
Moreover, chemical imaging provides a technology to perform high- 
throughput IR-spectroscopy by imaging multiple samples at once. 
It should be noted that the aforementioned studies were performed 
with the MIR region of the electromagnetic spectrum, as it known to 
represent secondary structure motifs (see Section 2.4). Though not yet 
realized, chemical imaging in the THz range may be of interest for 
conformational stability assessment, as thermodynamic changes rele-
vant during protein unfolding are detectable in the THz range [231]. For 
example, the effect of different structural conformations of bovine serum 
albumin on the surrounding water molecules was detected with THz 
time-domain spectroscopy [232]. The inverse analysis, where the THz 
range is employed to determine the protein’s conformational changes, 
was shown for bovine serum albumin [233] and pepsin [234]. These 
recent spectroscopic studies show promising results for potential THz 
imaging applications with regard to protein conformational stability. 
4.6. Protein cloud-point temperature 
Temperature recordings can also be a part of an analytical method, as 
is done for the determination of the protein cloud-point temperature 
(TCloud). The TCloud is defined as the temperature at which a solution 
displays liquid–liquid phase separation, where the protein-dense phase 
causes a change in solution turbidity (see Fig. 4H). The temperature 
value at which this phenomenon occurs depends mainly on the pro-
tein–protein interaction strength [235], and can be used to assess 
colloidal stability [236]. Imaging-based approaches have been devel-
oped to determine the change in solution turbidity as a function of 
temperature [130,139], which serve as an alternative for visual in-
spection [237], light transmittance [238], spectroscopy [239,240], and 
light scattering [241–244]. Several approaches have been tested to 
detect the turbidity change, such as identifying a decrease in mean gray 
pixel intensity [139], an increase in binary intensity difference 
compared to the starting point image [130], and the total number of 
white pixels [129]. A representative example of turbidity change is 
shown in Fig. 7a. Though the information content between set ups for 
light transmittance, light scattering, spectroscopic, and imaging does 
not differ, the main benefit of employing an imaging-based approach is 
the hardware simplicity, measurement speed, and its compatibility for 
miniaturization and high-throughput screening [130,139]. Between 
2005 and 2020, image-based methodologies for TCloud determination 
have mainly evolved regarding a higher sample throughput and 
streamlined data analytical workflow, where more recent studies start to 
focus on automated data evaluation and enhanced data mining. 
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4.7. Surface tension 
Quantification of apparent protein surface hydrophobicity is of in-
terest during biopharmaceutical characterization studies as it provides 
information on the presence and strength of protein–protein in-
teractions, protein-additive interactions, and interface/surface adsorp-
tion [245], all of which may affect product safety and efficacy. A 
parameter to quantify the apparent protein surface hydrophobicity is the 
surface tension [246,247]. There is a wide variety of analytical methods 
available to determine the surface tension, also referred to as tensiom-
etry [248,249]. The axisymmetric droplet shape analysis (ADSA) 
method employs imaging, which can be performed with pendant drop-
lets (hanging from a tip) and sessile droplets (deposited on a surface) 
[140,142]. ADSA uses the visible light range and the light source is 
placed behind or above the droplet, where a diffuser is sometimes placed 
between the light source and the sample. The droplet shape is extracted 
from the images, which is compared to a theoretical drop profile. The 
difference between the two droplet profiles allows one to quantify the 
surface tension, where a large deviation relates to a low surface tension, 
which in turn translates to a more hydrophobic protein surface. Ad-
vantages of the ADSA method compared to other surface tension mea-
surements includes a robust analysis, the ability to perform the 
experiment completely automated, the possibility to run dynamic 
measurements, and the relatively simple implementation in the lab 
[250]. Surface tension measurements by means of ADSA have shown to 
be applicable to assess aggregation tendency as well as packaging or 
delivery material compatibility. Relevant example of studies using the 
ADSA method within the scope of this review include an investigation on 
the interaction of proteins with liquid–liquid as well as solid–liquid in-
terfaces (Fig. 7c) [143], the evaluation of different insulins and their 
adsorption behavior as a function of concentration and pH [141], and a 
study on the interaction between protein A and an IgG antibody [144]. 
5. Future perspective 
This review presents the current applicability of imaging for the 
development and characterization of protein-based biopharmaceutical 
formulations, where spatial information obtained from the UV, visible, 
and IR region of the electromagnetic spectrum provides a wide range of 
valuable knowledge. As imaging possibilities will continue to develop 
along the electromagnetic spectrum, it is foreseen that imaging will play 
a pivotal role in the establishment of novel non-invasive, high- 
throughput, and multiplexed analytics. The summary provided in 
Table 1 shows that visible light imaging was found to be suitable for 
most current applications, which is considered to be a result of the 
relatively simple configuration as well as low costs for the image 
acquisition devices. Contrarily, the FIR region was not applied in studies 
considered relevant for the field of protein-based biopharmaceutical 
formulation characterization and development. Nevertheless, FIR-based 
spectroscopic studies have been reported on, and considering the evo-
lution of NIR and MIR imaging, it may be a only a matter of time before 
FIR imaging will used to capture protein hydration effects or high-order 
structures in a spatial dimension. 
In addition to expansion of the applied electromagnetic spectrum 
range, it is considered key for future research to focus on covering 
multiple sections of the electromagnetic spectrum in a single measure-
ment. For example, a biopharmaceutical characterization study to 
determine freeze/thaw effects would benefit from combining object 
identification by means of visible light to identify phase transitions, 
sample temperature distribution monitoring by thermal imaging, and 
molecular species identification and distribution by means of chemical 
imaging in a single measurement. This is regarded beneficial as it allows 
for mutually exclusive as well as complementary data, which will enrich 
fundamental understanding and simplify computer-aided analytical 
interpretation. Initially, such an analytical device would be technically 
and economically challenging, but efforts to work towards multiplexed 
analytical imaging possess a great opportunity to gain enhanced 
fundamental understanding without sample interference in a high- 
throughput manner. In addition to fundamental understanding, multi-
plexed imaging would increase the added value of imaging as PAT tool, 
considering that imaging in its current form is already indicated as an 
interesting non-invasive analytical technique for future PAT approaches 
[251,252]. 
Work covered in this review showed how recent studies focus on 
developing experimental instrumentation with low material usage and a 
high sample throughput. Consequently, the aim of imaging-based bio-
pharmaceutical characterization studies shifts from experimental ad-
justments towards the computational side, where the implementation of 
advanced data analytics is explored to effectively use the ever-increasing 
data complexity. This is most evident in the studies that apply imaging to 
investigate phase transitions in liquid formulations, were data sets can 
range from hundreds up to tens of thousands of images that have to be 
interpreted. However, the performance of data analytical workflows and 
the applied (un)supervised machine learning models needs to be care-
fully evaluated and validated to ensure that these computational efforts 
actually improve the methodologies. It should be noted that the 
observed inconsistency between employed evaluation parameters im-
pairs study comparability and reproducibility, as performance results 
are solely presented by a (subjective) selection of evaluation parameters, 
without proper access to the underlying data. To ensure study compa-
rability and reproducibility of novel data analytical approaches applied 
to data obtained from imaging-based experimental equipment, guide-
lines for performance evaluation and data transparency should be 
formulated and maintained. 
Advancement and exploration of computational workflows will 
remain to play an important role for analytical imaging in biopharma-
ceutical characterization studies. For instance, the effects of different 
image segmentation or transformation techniques is largely uncharted 
territory, and further exploration will be able to enhance the informa-
tion content of already existing data. Not only segmentation and trans-
formation will open up the available information content of the data, but 
also the application of deep learning approaches will be utilized more 
often, as it offers the ability to analyze complex data sets. Nevertheless, 
deep learning approaches require a data set size or data set balance that 
is often not obtained with biopharmaceutical characterization studies. 
In order to overcome such data set size challenges, implementation of 
data augmentation strategies (also referred to as transfer learning) is a 
route to consider, as these strategies provide the sample numbers and 
variation required to train the respective algorithms. 
In conclusion, the current position that imaging obtained in the 
analytical toolbox employed for the characterization and development 
of protein-based biopharmaceutical formulations is a result of the 
combined effort of many research groups. Imaging has become widely 
accessible and applicable because these research groups developed im-
aging instrumentation outside the visible light range, while effectively 
employing the high-throughput and non-invasive nature of imaging. As 
seen for other analytical techniques applied for characterization and 
development studies in the field of biopharmaceuticals, such as spec-
troscopic techniques, it is not unlikely that imaging approaches will be 
fitted to meet the measurement requirements for monitoring during 
bioprocessing as PAT technology, where it may find a place in the field 
of non-invasive process control procedures and real-time release 
strategies. 
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[133] A.K. Wöll, J. Schütz, J. Zabel, J. Hubbuch, Analysis of phase behavior and 
morphology during freeze-thaw applications of lysozyme, Int. J. Pharm. 555 
(2019) 153–164. 
[134] D. Colucci, D. Fissore, A.A. Barresi, R.D. Braatz, A new mathematical model for 
monitoring the temporal evolution of the ice crystal size distribution during 
freezing in pharmaceutical solutions, Eur. J. Pharm. Biopharm. 148 (2020) 
148–159. 
[135] D. Colucci, R. Maniaci, D. Fissore, Monitoring of the freezing stage in a freeze- 
drying process using IR thermography, Int. J. Pharm. 566 (2019) 488–499. 
[136] U. Roessl, D. Jajcevic, S. Leitgeb, J.G. Khinast, B. Nidetzky, Characterization of a 
laboratory-scale container for freezing protein solutions with detailed evaluation 
of a freezing process simulation, J. Pharm. Sci. 103 (2014) 417–426. 
[137] A. Hedoux, L. Paccou, S. Achir, Y. Guinet, Mechanism of protein stabilization by 
trehalose during freeze-drying analyzed by in situ micro-raman spectroscopy, 
J. Pharm. Sci. 102 (2013) 2484–2494. 
[138] T. Starciuc, B. Malfait, F. Danede, L. Paccou, Y. Guinet, N.T. Correia, A. Hedoux, 
Trehalose or Sucrose: Which of the Two Should be Used for Stabilizing Proteins in 
the Solid State? A Dilemma Investigated by In Situ Micro-Raman and Dielectric 
Relaxation Spectroscopies During and After Freeze-Drying, J. Pharm. Sci. 109 
(2020) 496–504. 
[139] J. Pincemaille, A. Banc, E. Chauveau, J.-M. Fromental, L. Ramos, M.-H. Morel, 
P. Menut, Methods for screening cloud point temperatures, Food Biophys. 13 
(2018) 422–431. 
[140] P. Cheng, D. Li, L. Boruvka, Y. Rotenberg, A. Neumann, Automation of 
axisymmetric drop shape analysis for measurements of interfacial tensions and 
contact angles, Colloids Surf. 43 (1990) 151–167. 
[141] F. Lin, D. Kwok, Z. Policova, W. Zingg, A. Neumann, The effect of ph and 
concentration on the surface tension of adsorbed layers of various insulin 
preparations, Colloids Surf., B 3 (1995) 281–286. 
[142] Y. Rotenberg, L. Boruvka, A. Neumann, Determination of surface tension and 
contact angle from the shapes of axisymmetric fluid interfaces, J. Colloid 
Interface Sci. 93 (1983) 169–183. 
[143] A. Voigt, O. Thiel, D. Williams, Z. Policova, W. Zingg, A. Neumann, Axisymmetric 
drop shape analysis (ADSA) applied to protein solutions, Colloids Surf. 58 (1991) 
315–326. 
[144] L. Yang, M. Biswas, P. Chen, Study of binding between protein A and 
immunoglobulin G using a surface tension probe, Biophys. J . 84 (2003) 509–522. 
[145] ISO/FDIS 26924:2013. Particle characterization of particulate systems. 
Vocabulary., in. 
[146] L.O. Narhi, J. Schmit, K. Bechtold-Peters, D. Sharma, Classification of protein 
aggregates, J. Pharm. Sci. 101 (2012) 493–498. 
[147] A.S. Rosenberg, Effects of protein aggregates: an immunologic perspective, AAPS 
J. 8 (2006) E501–E507. 
[148] J.G. Barnard, K. Babcock, J.F. Carpenter, Characterization and quantitation of 
aggregates and particles in interferon-β products: potential links between product 
quality attributes and immunogenicity, J. Pharm. Sci. 102 (2013) 915–928. 
[149] C.F. Chisholm, B.H. Nguyen, K.R. Soucie, R.M. Torres, J.F. Carpenter, T. 
W. Randolph, In vivo analysis of the potency of silicone oil microdroplets as 
immunological adjuvants in protein formulations, J. Pharm. Sci. 104 (2015) 
3681–3690. 
[150] V. Corvari, L.O. Narhi, T.M. Spitznagel, N. Afonina, S. Cao, P. Cash, I. Cecchini, M. 
R. DeFelippis, P. Garidel, A. Herre, Subvisible (2–100 μm) particle analysis during 
biotherapeutic drug product development: Part 2, experience with the application 
of subvisible particle analysis, Biologicals 43 (2015) 457–473. 
[151] S.K. Singh, N. Afonina, M. Awwad, K. Bechtold-Peters, J.T. Blue, D. Chou, 
M. Cromwell, H.J. Krause, H.C. Mahler, B.K. Meyer, An industry perspective on 
the monitoring of subvisible particles as a quality attribute for protein 
therapeutics, J. Pharm. Sci. 99 (2010) 3302–3321. 
[152] V. Filipe, A. Hawe, J.F. Carpenter, W. Jiskoot, Analytical approaches to assess the 
degradation of therapeutic proteins, TrAC, Trends Anal. Chem. 49 (2013) 
118–125. 
[153] C.-T. Huang, D. Sharma, P. Oma, R. Krishnamurthy, Quantitation of protein 
particles in parenteral solutions using micro-flow imaging, J. Pharm. Sci. 98 
(2009) 3058–3071. 
[154] S. Cao, L. Narhi, Y. Jiang, R.S. Rajan, Analytical methods to measure subvisible 
particulates, in: Analysis of aggregates and particles in protein pharmaceuticals, 
Wiley Online Library, 2012, pp. 85-115. 
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